Аннотация:
In this study, we studied the activity of three antibacterial drugs: Cefotaxime (Claforan, France), Ceftriaxone (Russia) and Doxycycline (Russia). The control group is a pentavalent antimony drug - Glucantim (France), which has been the "gold standard" for a long time in the treatment of any form of leishmaniasis. During the experiments, the leading positions of doxycycline and ceftriaxone established in vitro. Minimal doses of both drugs lead to absolute suppression of the mobility of the pathogen L. major. Increasing the therapeutic dose of drugs is not justified. Comparison of these drugs with the gold standard of therapy with meglumine antimonate (glucantim) showed their superiority in all indicators.
Акулинина И.
Чебышев Н. В. Николай Васильевич 1935-
Беречикидзе И. А. Иза Автандиловна 1962-
Горожанина Е. С. Елена Сергеевна 1972-
Богомолов Д.
Akulinina I.
Cheby'shev N. V. Nikolay Vasilyevich 1935-
Berechikidze I. A. Iza Avtandilovna 1962-
Gorozhanina E. S. Elena Sergeevna 1972-
Bogomolov D.
COMPARISON OF THE EFFECTIVENESS OF DRUGS FOR THE TREATMENT OF CUTANEOUS LEISHMANIASIS IN VITRO
Текст визуальный непосредственный
Georgian Medical News
Ассоциация деловой прессы Грузии
Вып. 289 С. 151-157
2019
Статья
antiprotozoal agent human Russian Federation skin leishmaniasis Antiprotozoal Agents Humans Leishmaniasis, Cutaneous Russia
In this study, we studied the activity of three antibacterial drugs: Cefotaxime (Claforan, France), Ceftriaxone (Russia) and Doxycycline (Russia). The control group is a pentavalent antimony drug - Glucantim (France), which has been the "gold standard" for a long time in the treatment of any form of leishmaniasis. During the experiments, the leading positions of doxycycline and ceftriaxone established in vitro. Minimal doses of both drugs lead to absolute suppression of the mobility of the pathogen L. major. Increasing the therapeutic dose of drugs is not justified. Comparison of these drugs with the gold standard of therapy with meglumine antimonate (glucantim) showed their superiority in all indicators.